Should I add gemfibrozil to a patient who is already on the maximum dose of amlodipine (10 mg daily) with uncontrolled hypertension, and who may have elevated triglycerides?

No, do not add gemfibrozil for uncontrolled hypertension

Gemfibrozil is not indicated for the treatment of hypertension and will not help control your patient's blood pressure. You appear to be confusing lipid management with blood pressure management—these are separate therapeutic targets requiring different medications.

Why Gemfibrozil is Not Appropriate Here

Gemfibrozil is a fibric acid derivative indicated specifically for:

• Severe hypertriglyceridemia (triglycerides ≥500 mg/dL) to prevent pancreatitis 1
• Type IIb dyslipidemia with the triad of low HDL-cholesterol, elevated LDL-cholesterol, AND elevated triglycerides (>200 mg/dL) after failure of other lipid therapies, in patients without existing coronary disease 1

Gemfibrozil has no antihypertensive properties. Research in animal models showed it lowers triglycerides through increased lipoprotein lipase activity in skeletal muscle, not through any blood pressure-lowering mechanism 2.

What You Should Actually Do for Uncontrolled Hypertension

Since your patient is on maximum-dose amlodipine (10 mg daily) with uncontrolled hypertension, you need to add additional antihypertensive agents, not lipid-lowering drugs:

First-Line Add-On Options 3, 4:

• Thiazide/thiazide-like diuretic (Grade A evidence)
• ACE inhibitor (Grade B evidence, if not black)
• ARB (Grade B evidence)
• Beta-blocker (if patient <60 years, Grade B)

The combination of a calcium channel blocker (amlodipine) plus either a thiazide diuretic or an ACE inhibitor/ARB is well-supported 3.

Target Blood Pressure

Aim for SBP <130 mm Hg in most patients with hypertension 4.

If Your Patient Also Has Elevated Triglycerides

Only consider gemfibrozil if your patient separately meets lipid criteria:

When Gemfibrozil May Be Appropriate 5, 6:

• Triglycerides ≥500 mg/dL: Fibrate or niacin before LDL-lowering therapy to prevent pancreatitis (Class I recommendation)
• Triglycerides 200-499 mg/dL: Gemfibrozil can be useful as add-on therapy AFTER LDL-lowering with statins, particularly if HDL <40 mg/dL (Class IIa recommendation, Level B evidence)

Critical Safety Concerns with Gemfibrozil 7, 8:

• The combination of gemfibrozil plus statin carries increased risk of severe myopathy and rhabdomyolysis
• If combination therapy is needed, fenofibrate is preferred over gemfibrozil when used with statins
• One death from rhabdomyolysis was documented in a patient on gemfibrozil-simvastatin combination who didn't meet treatment guidelines 9
• Statin doses should be kept relatively low when combined with fibrates 5

Lipid Management Hierarchy 8, 10:

1. Lifestyle modifications first: Diet, exercise, weight loss, alcohol restriction
2. Statin therapy for LDL-cholesterol lowering (first-line for ASCVD risk reduction)
3. Consider fibrate or niacin only after optimizing statin therapy, if triglycerides remain elevated

Common Pitfall to Avoid

Do not confuse dyslipidemia management with hypertension management. The fact that both conditions often coexist (metabolic syndrome) does not mean one drug treats both. Your patient needs:

• Antihypertensive medication to control blood pressure
• Separate evaluation of lipid panel to determine if lipid-lowering therapy is indicated

Add a second antihypertensive agent from the first-line options above, then reassess blood pressure control before considering any additional medications.